US Patent 11358969 Indole AHR inhibitors and uses thereof

Patent 11358969 was granted and assigned to Ikena Oncology on June, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Ikena Oncology

Current Assignee

Ikena Oncology

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11358969

Date of Patent

June 14, 2022

Patent Application Number

16843606

Date Filed

April 8, 2020

Patent Citations

‌

US Patent 10570138 Indole AHR inhibitors and uses thereof

Patent Citations Received

‌

US Patent 12077542 Indole AHR inhibitors and uses thereof

‌

US Patent 11591339 Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors

Patent Primary Examiner

‌

Po-Chih Chen

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11358969 Indole AHR inhibitors and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API